Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 17/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 16/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409571 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7216415 | 0.86 | EGFR (0.84) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220753 | 0.85 | EGFR (0.84) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220739 | 0.84 | EGFR (0.83) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL2993868 | 0.83 | EGFR (1.00) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220678 | 0.81 | EGFR (0.75) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220061 | 0.81 | EGFR (0.79) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220144 | 0.81 | EGFR (1.00) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7221044 | 0.80 | EGFR (0.91) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7243805 | 0.79 | EGFR (0.66) | EGFRERBB2ERBB4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | SANTARIS PHARMA A/S (DK) | 2012-03-29 | — | — | US | claimed |
| EP-2419110-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | Enzon Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| EP-2376087-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | Santaris Pharma A/S (DK) | 2011-10-19 | — | — | EP | claimed |
| WO-2010120861-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ENZON PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| WO-2010054051-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | SANTARIS PHARMA A/S (DK) | 2010-05-14 | — | — | WO | claimed |
| US-9815893-B2 | Anti-VEGF antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2894167-B1 | Anti-VEGF Antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2925778-B1 | ANTI-VEGF ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2555788-B1 | NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY. | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2493929-B1 | ANTI-EGFR ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2513148-B1 | ANTI-HER2 ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-20150343023-A1 | METHODS FOR CARDIOPROTECTION AND CARDIOREGENERATION WITH DIMERS OF EGF FAMILY LIGANDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20110117110-A1 | ANTI-EGFR ANTIBODIES AND THEIR USES | FACET BIOTECH CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011059762-A1 | ANTI-EGFR ANTIBODIES AND THEIR USES | ABBOTT BIOTHERAPEUTICS CORP. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100322931-A1 | ANTI-VEGF ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC. | 2010-12-23 | — | — | US | disclosed |
| WO-2010120861-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ENZON PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010082009-A1 | SCREENING ASSAY | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010033249-A2 | COMPOSITIONS OF AND METHODS USING LIGAND DIMERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2008157753-A1 | METHODS OF TREATMENT FOR SPINAL MUSCULAR ATROPHY | SMA FOUNDATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ERBB3, ERBB2, EGFR | EGFR 3/4885ERBB2 2/4885ERBB4 4/4885 |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ERBB3, ERBB2, EGFR | EGFR 3/4885ERBB2 2/4885ERBB4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.